Acquired von Willebrand Disease in Myeloproliferative Disorders

References

• Ruggeri Z. M., Ware J. The structure and function of von Willebrand factor. Thromb. Haemost. 1992; 67: 594–599
   PubMed Web of Science ®Google Scholar
• Leupin L., Beck E. A., Furian M., Bucher U. Hämostasestörung mit verminderter Aktivität des von Willebrand Faktors bei myeloproliferativen Syndromen. Schweiz. Med. Wschr. 1983; 113: 713–716
   PubMedGoogle Scholar
• Budde U., Schaefer G., Mueller N., Egli H., Dent J., Ruggeri Z., Zimmerman T. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984; 64: 981–985
   PubMed Web of Science ®Google Scholar
• Budde U., Dent J. A., Berkowitz S. D., Ruggeri Z. M., Zimmerman T. S. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 1986; 68: 1213–1217
   PubMed Web of Science ®Google Scholar
• Fabris F., Casonato A., Del Ben M. G., De Marco L., Girolami A. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br. J. Haematol. 1986; 63: 75–83
   PubMed Web of Science ®Google Scholar
• Casonato A., Fabris F., Zancan L., Girolami A. Acquired type I von Willebrand's disease in a patient with essential thrombocytosis. Acta. Haematol. 1986; 75: 188–189
   PubMed Web of Science ®Google Scholar
• Mohri H. Acquired von Willebrand disease in patients with polycythemia rubra vera. Am. J. Hematol. 1987; 26: 135–146
   PubMed Web of Science ®Google Scholar
• Mohri H., Ohkubo T. Acquired von Willebrand's syndrome due to an inhibitor of IgG specific for von Willebrand's factor in polycythemia rubra vera. Acta. Haematol. 1987; 78: 258–264
   PubMed Web of Science ®Google Scholar
• Lopez-Fernandez M. F., Lopez-Berges C., Martin R., Pardo A., Ramos F. J., Battle J. Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis. Thromb. Haemost. 1987; 58: 753–757
   PubMed Web of Science ®Google Scholar
• Raman K. S., Sawdyk M., Saeed S. M. Essential thrombocythemia with acquired von Willebrand's disease. Am. J. Clin. Pathol. 1987; 88: 102–106
   PubMed Web of Science ®Google Scholar
• Tatewaki W., Takahashi H., Shibata A. Multimeric composition of plasma von Willebrand factor in chronic myeloproliferative disorders. Clin. Lab. Haematol. 1988; 10: 417–425
   PubMedGoogle Scholar
• Tatewaki W., Takahashi H., Hanano M., Shibata A. Multimeric composition of plasma von Willebrand factor in chronic myelocytic leukaemia. Thromb. Res. 1988; 52: 23–32
   PubMed Web of Science ®Google Scholar
• Sato K. Plasma von Willebrand factor abnormalities in patients with essential thrombocythemia. Keio J. Med. 1988; 37: 54–71
   PubMedGoogle Scholar
• Casonato A., Fabris F., Cordiano I., Girolami A. Persistence of von Willebrand factor abnormalities in patients with myeloproliferative disease in spite of use of antiproteolytic mixture as anticoagulant. Eur. J. Haematol. 1988; 40: 284–285
   PubMed Web of Science ®Google Scholar
• Tatewaki W., Takahasi H., Takakuwa E., Wada K., Shibata A. Plasma von Willebrand factor proteolysis in patients with chronic myeloproliferative disorders: no possibility of ex vivo degradation by calcium-dependent proteases. Thromb. Res. 1989; 56: 191–199
   PubMed Web of Science ®Google Scholar
• Mazzucconi M. G., Ferrari A., Solinas S., Vitale A., Christolini A., Federici A. B., Mandelli F. Studies of von Willebrand factor in essential thrombocythemia treated with alpha-2b recombinant interferon. Haemostasis 1991; 21: 135–140
   PubMedGoogle Scholar
• Carter C., Boughton B. J. Acquired von Willebrand's disease in myeloproliferative syndrome: spontaneous remission during pregnancy. Thromb. Haemost. 1992; 67: 387–388
   PubMed Web of Science ®Google Scholar
• Murakawa M., Okamura T., Tsutsumi K., Tanoguchi S., Kamura T., Shibuya T., Harada M., Niho Y. Acquired von Willebrand's disease in association with essential thrombocythemia: regression following treatment. Acta. Haematol. 1992; 87: 83–87
   PubMed Web of Science ®Google Scholar
• Budde U., Scharf R., Franke P., Hartmann-Budde K., Dent J., Ruggeri Z. M. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993; 82: 1749–1757
   PubMed Web of Science ®Google Scholar
• van Genderen P. J. J., Michiels J. J., van der Poel-van de Luytgaarde S. C. P., van Vliet H. H. D.M. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Ann. Hematol. 1994; 69: 81–84
   PubMed Web of Science ®Google Scholar
• Fenaux P., Simon M., Caulier T. M., Lai J. L., Goudemand J. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549–556
   PubMed Web of Science ®Google Scholar
• Bellucci S., Janvier M., Tobelem G., Flandrin G., Charpak Y., Berger R., Boiron M. Essential thrombocythemias: clinical, evolutionary and biological data. Cancer 1986; 58: 2440–2447
   PubMed Web of Science ®Google Scholar
• van Genderen P. J. J., Michiels J. J. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse. Med. 1994; 23: 73–77
   PubMed Web of Science ®Google Scholar
• Casonato A., Fabris F., Boscaro M., Girolami A. Increased factor VIII/vWF levels in patients with reduced platelet number. Blut 1987; 54: 281–288
   PubMedGoogle Scholar